Q2 revenues down 11%, net down 66%

Discussion in 'Merck' started by anonymous, Jul 28, 2015 at 8:46 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    uh oh.
     

  2. anonymous

    anonymous Guest

    The outcome gives the green light for large downsizing and the employer mandate assures the action to occur.
     
  3. anonymous

    anonymous Guest

    Way to demonstrate top performance Kenny. Modeling excellence?
     
  4. anonymous

    anonymous Guest

    Saw Kenny on TV this morning on CNBC being interviewed about results and he was spinning so hard I bet he is drunk from all the spinning. Things sure don,t look so good for the future. It,s hard to understand the revenue miss with the stellar Mgnt and marketing teams. What Merck marketing doesn't know hasn't been thought of yet.
    Kenny said the pipeline was great and they had the right plans in place. No worries.....
     
  5. anonymous

    anonymous Guest

    He better hope that Mercks pipeline starts producing something. Soon.
     
  6. anonymous

    anonymous Guest

    What about Grasstek? Liptruzet? Huh?
     
  7. anonymous

    anonymous Guest

    I agree! Belsomra, is a dud. Plenty of initial scripts but too many failures = very few refills
    • Januvia/Janumet had sales of $1.60 billion, up 1%.
    • Zetia/Vytorin had sales of $955 million, down 16%.
    Don't know who's sells these two
    • Remicade had sales of $455 million, down 25%.
    • Isentress had sales of $375 million, down 17%.
    Vaccines
    • Gardasil/Gardasil 9 had sales of $427 million, up 4%.
    • Proquad, M-M-R 2 and Varivax had sales of $358 million, down 10%.
    • Cubicin had sales of $293.
     
  8. anonymous

    anonymous Guest

    Grasstek is an important part of our allergy portfolio. Liptruzet is gone so what's your point?
     
  9. anonymous

    anonymous Guest

    What are YTD sales for Grasstek and Ragtek? Are they viable?
     
  10. anonymous

    anonymous Guest

    Better refine those resumes!
     
  11. anonymous

    anonymous Guest

    Merck always wanted to be like Pfizer. Merck quarterly sales $9.79b. Pfizer 12 billion. Merck set sights and undershot.
     
  12. anonymous

    anonymous Guest

    What about Keytruda? No mention?
     
  13. anonymous

    anonymous Guest

    It must not be generating Billions nor Millions. Only the top money making products were mentioned.
     
  14. anonymous

    anonymous Guest

    You are not selling enough off label to qualify
     
  15. anonymous

    anonymous Guest

    Forget about MRL, there is no pipeline. I work at the Boston site and believe me it's a graveyard of activity. It's been nearly 2.5 years since Roger took over and it's never been quieter.
     
  16. anonymous

    anonymous Guest

    Only people left a Merck are the ones that feel hand cuffed. They want you to think that a reason to stay is the pension. I did the math and it wasn't. Opportunity came knocking so I left. More money and better upside potential in the pipeline. Merck isn't viewed as the company it was, certainly not as respected as it once was. The company I went to is viewed as a leader in their space and I've been told by my docs that they have always respected the reps for their knowledge and the way they conduct them selves, more of a consultant than a sales person. Merck is going to have to change its ways if it wants to keep up. Docs aren't going to keep supporting Merck just because it's Merck. That's evident by how sales are faltering. Good luck to you all, there is life after Merck.
     
  17. anonymous

    anonymous Guest

    Listen up! He clearly said Merck is getting out of Primary Care! Its all about the Oncology pipeline.
     
  18. anonymous

    anonymous Guest

    the culture and the talent pool of leaders is pathetic. as they say the fish starts to rot from its head. Mrk is a ship without a rudder.
     
  19. anonymous

    anonymous Guest

    Keytruda, generated $110 million in sales in the second quarter, with a total of $192 million so far this year.
     
  20. anonymous

    anonymous Guest

    Pathetic sales better accelerate that sales line or you will be soon departed.